Navigation Links
Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:8/27/2010

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on August 25, 2010 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 10,000 shares of common stock to two new employees.

Both of the stock options are intended to be incentive stock options to the extent permitted by law and both have an exercise price per share equal to $4.53, the fair market value on the grant date. Each stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to the new employee’s continued service relationship with the Company on each such date. Each stock option has a ten year term and is subject to the terms and conditions of the Company's 2007 Equity Incentive Award Plan and the stock option agreement pursuant to which the option is granted.

Both stock options were granted as an inducement material to the new employees entering into employment with Orexigen Therapeutics in accordance with NASDAQ listing Rule 5635(c)(4).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave(R). The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010
2. Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
3. Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R)
4. Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
5. Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009
6. Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
7. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
8. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
9. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
11. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
(Date:1/19/2017)... -- The U.S. Food and Drug Administration today approved Trulance ... adult patients. "No one medication works for ... Beitz , M.D., director of the Office of Drug Evaluation ... "With the availability of new therapies, patients and their doctors ... ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... 2017 , ... Medical lab testing through hospitals and other traditional ... test will take days to arrive to the end customer, having to travel through ... their lab tests, bypassing the cost and delay of traditional means. Now all employees ...
(Date:1/21/2017)... ... ... Salveo for life, a company that distributes an effervescent lime-flavored drink called ... part of its presence to expand its market reach. , Using a formula developed ... nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, whilst supporting ...
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of ... vision of its owner and founder. As Oat is recognized globally as one of ... knows personally as he believes it is a move to sow the seed of ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate ... the electrifying line-up of events for its annual meeting “Coming Home 2017,” an ... “Coming Home 2017” will be held on Friday January 27 through Sunday, ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... the opening of its new medical office in Petaluma, located at 167 Lynch ... casting room, access to SRO sports medicine and rehabilitation services and ...
Breaking Medicine News(10 mins):